News

2023

2022

2021

2020

Apr 26, 2023
Mindset Pharma Files Two Patent Applications for its Non-Hallucinogenic Non-Tryptamine Compounds
Read more
Read more
Mindset Pharma Files Two Patent Applications for its Non-Hallucinogenic Non-Tryptamine Compounds
Apr 26, 2023
Read more
Read more
Apr 03, 2023
Mindset Pharma to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023
Read more
Read more
Mindset Pharma to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023
Apr 03, 2023
Read more
Read more
Mar 28, 2023
Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders Discussing Expansion of Drug Discovery Efforts into Novel Non-Hallucinogenic Therapeutics
Read more
Read more
Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders Discussing Expansion of Drug Discovery Efforts into Novel Non-Hallucinogenic Therapeutics
Mar 28, 2023
Read more
Read more
Mar 14, 2023
Mindset Pharma To Defend Against Lawsuit Filed By Reunion Neurosciences
Read more
Read more
Mindset Pharma To Defend Against Lawsuit Filed By Reunion Neurosciences
Mar 14, 2023
Read more
Read more
Mar 06, 2023
Mindset Pharma and PharmAla Complete First Sale of Pharmaceutical Grade Psilocybin Into Growing Australian Market via Sales Partnership
Read more
Read more
Mindset Pharma and PharmAla Complete First Sale of Pharmaceutical Grade Psilocybin Into Growing Australian Market via Sales Partnership
Mar 06, 2023
Read more
Read more
Feb 02, 2023
Mindset Pharma Receives Another Allowance from USPTO for Patent Application Expanding Composition of Matter for Family 1 Psilocybin Analogs
Read more
Read more
Mindset Pharma Receives Another Allowance from USPTO for Patent Application Expanding Composition of Matter for Family 1 Psilocybin Analogs
Feb 02, 2023
Read more
Read more
Jan 20, 2023
Mindset Pharma Receives Allowance for U.S. Patent Application Covering Composition of Matter for Its Lead Psychedelic Therapeutic Candidate, MSP-1014, And Additional Family 1 Tryptamine Prodrug Candidates
Read more
Read more
Mindset Pharma Receives Allowance for U.S. Patent Application Covering Composition of Matter for Its Lead Psychedelic Therapeutic Candidate, MSP-1014, And Additional Family 1 Tryptamine Prodrug Candidates
Jan 20, 2023
Read more
Read more
Get to know us
Let Us Help You
Join the Conversation
Linkedin Youtube Instagram Facebook
Subscribe
Get Updates
Copyright © 2023 Mindset Pharma All rights reserved. | Disclaimer & Privacy Policy
Subscribe for latest news